We found that dapagliflozin had similar cost-effectiveness among patients with and without diabetes ( )
51 per additional QALY
“Lowering the annual cost of SGLT2-Is to $1,431—a 68% reduction from the current Veterans Affairs price and a 78% reduction in wholesale acquisition cost, which
Sensitivity analyses revealed that the addition of dapagliflozin to the standard treatment demonstrated an 87% cost-effectiveness strategy at a level of
We aim to determine the cost-effectiveness of dapagliflozin in addition to standard therapy versus standard therapy alone among patients with heart failure with
Compared to first-line metformin monotherapy followed by gradual addition of dapagliflozin, first-line use of combination dapagliflozin and metformin is likely to be a
35
72 (minimum value) to $7081
Compared with glimepiride, dapagliflozin as monotherapy for T2DM is a more cost-effective treatment for T1DM patients on monotherapy in China and the weight control has been identified as the major contributor for the higher cost-effectiveness
5th and 97
2 Alternatively, basal insulin is administered with oral antidiabetic drugs (OADs) (basal insulin In addition, the authors found that a 43% drop in dapagliflozin cost—from $424 to $270 per month—would subsequently reduce the cost per QALY gained to below $50,000, or 40% less
The cost of combination dapagliflozin and metformin per day was AUD $2
Recent economic analyses of the DAPA-HF trial reported that dapagliflozin provided additional health benefits in patients with HFrEF, incurring additional costs which fell within traditional thresholds for good value in health care
Therefore, the drug cost
This study aimed to assess the long-term cost-effectiveness of dapagliflozin versus DPP-4i, as dual oral therapies in The cost of dapagliflozin per cycle ($64
Dapagliflozin is a cost-saving alternative to dipeptidyl peptidase-4 (DPP-4) inhibitors when added to metformin plus sulfonylurea for the treatment of patients with type 2 diabetes mellitus (T2DM), according to a study from the Netherlands
These costs are driven by a combination of increased drug acquisition Cost analysis results show that the total cost per patient was € 56,984 with dapagliflozin and € 59,905 with placebo, saving € 2,921 per patient (Table 4)
HHF, urgent HF visits and cardiovascular deaths avoided provided important cost offsets to expenditure on dapagliflozin (Table 3)